2016
Immuno-oncology combinations: raising the tail of the survival curve
Abstract: There have been exponential gains in immuno-oncology in recent times through the development of immune checkpoint inhibitors. Already approved by the U.S. Food and Drug Administration for advanced melanoma and non-small cell lung cancer, immune checkpoint inhibitors also appear to have significant antitumor activity in multiple other tumor types. An exciting component of immunotherapy is the durability of antitumor responses observed, with some patients achieving disease control for many years. Nevertheless, n…
Search citation statements
Paper Sections
Select...
65
23
22
3
Citation Types
1
76
0
4
Year Published
2016
2026
Publication Types
Select...
96
4
4
3
Relationship
1
106
Authors
Journals
Cited by 104 publications
(81 citation statements)
References 145 publications
1
76
0
4
“…Furthermore, transcriptome analysis of tumorâinfiltrating immune cells in mice treated with the combination therapy revealed that this treatment also reduced the expression of the inflammatory cytokine interleukinâ6 (ILâ6), angiogenic factor vascular endothelial growth factor A (VEGFA), and immunosuppressive enzyme arginase [ 44 , 45 , 46 , 47 ]. These immuneâactivating effects collectively resulted in significant tumor reduction and longâterm âtailâofâtheâcurveâ survival benefits in tumorâbearing mice, as demonstrated in our study and in previous studies [ 18 , 19 , 20 , 21 , 48 , 49 ].…”
Section: Discussionsupporting
confidence: 86%
“…Furthermore, transcriptome analysis of tumorâinfiltrating immune cells in mice treated with the combination therapy revealed that this treatment also reduced the expression of the inflammatory cytokine interleukinâ6 (ILâ6), angiogenic factor vascular endothelial growth factor A (VEGFA), and immunosuppressive enzyme arginase [ 44 , 45 , 46 , 47 ]. These immuneâactivating effects collectively resulted in significant tumor reduction and longâterm âtailâofâtheâcurveâ survival benefits in tumorâbearing mice, as demonstrated in our study and in previous studies [ 18 , 19 , 20 , 21 , 48 , 49 ].…”
Section: Discussionsupporting
confidence: 86%
“…One of the key goals for future immunotherapy strategy is to "raise the tail" of the survival curve. 35 Our findings underscore the relevance of an early immunological biomarker response to the overall survival benefit and its potential utility as an early readout to inform dose and treatment decisions in drug development and clinical practice. The analyses performed by Bruno et al 36 indicate the correlation of tumor growth rate (K growth ) estimated by TGI models as a good predictor of survival.…”
Section: Discussionmentioning
confidence: 63%
“…Immunotherapy is given with the aim of gaining durable disease control [19]. This study provides evidence that the likelihood of achieving disease control is similar between patients with acral cutaneous melanoma and those with non-acral cutaneous melanoma.…”
Section: Discussionmentioning
confidence: 73%
